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tion was built (Tableau 8) to visualize the information to be easily communicated to 
local authorities and clinicians. Results: A middle-sized Finnish municipality with 
74 168 inhabitants (Joensuu) was chosen as a case-example. The estimated num-
ber of diabetic patients was 2267, out of which 1678 had T2D. Within three years 
among patients with T2D, the predicted number of CHD events would be 73 and 
57 for HbA1c levels 6.5% and 8.0%, respectively, resulting total of 16 avoidable CHD 
events. ConClusions: By bringing the understanding of epidemiology and treat-
ment effects to local level, there is a possibility to show the positive outcomes of good 
diabetes care in real practice. This information may be used to help budget holders 
in resource allocation and to motivate authorities, clinicians (and patients) to follow 
the diabetes treatments guidelines.
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objeCtives: To obtain information regarding the presence of cardiometabolic risk 
factors among adrenal insufficiency (AI) patients in Italy. To understand treatment 
patterns and goals and to gain consensus regarding how effectively existing therapies 
meet these goals. Methods: A two-stage Delphi process was conducted with four 
Italian key opinion leaders (KOLs). Each KOL completed an electronic survey eliciting 
information regarding AI management and the prevalence and importance of risk 
factors. To reach a consensus on the key issues, the results were discussed at a face-
to-face meeting. Results: The KOLs agreed that avoiding adrenal crisis is the main 
treatment goal, and that quality of life and avoiding fatigue are most important to 
patients. Patients typically receive 20–30 mg cortisone acetate or hydrocortisone daily 
in 2-3 administrations. A consensus was reached that cardiometabolic risk factors 
are not hallmarks of AI, but are related to its glucocorticoid replacement treatment 
(GC) either due to overtreatment or non-physiological replacement of serum cortisol. 
In agreement with the available evidence in the literature they suggested that the 
increase risk may be associated with the non-physiological cortisol peaks and troughs 
that are characteristic of the existing GC replacement therapies. They established that 
50% of AI patients are over treated, often to minimise the risk of adrenal crisis and all 
patients currently face non-physiological cortisol replacement, given the available 
treatments. GC replacement–related risks included (prevalence in AI in parenthe-
ses): hypertension (10–30%), abdominal obesity (15–35%), dyslipidaemia (33%) and 
metabolic syndrome (30–35%). ConClusions: The prevalence of cardiometabolic 
risk factors is associated with the treatment of AI, not AI itself. Over-treatment and 
non-physiological cortisol replacement may explain cardiometabolic risks. A physi-
ological alternative to existing treatments would be welcomed in Italy.
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objeCtives: Type 2 Diabetes mellitus (T2DM) is becoming a major chronic disease 
burden worldwide. Indians are known to have an increased predisposition for diabetes 
which has become an important health concern. The current analysis is aimed to 
systematically review medical literature on T2DM, its prevalence and complications in 
India and also explore the differential risk factors in sub-groups. Methods: Studies 
are being retrieved from Pubmed, Cochrane and Embase databases using relevant 
search strategies. Search limits are: articles in English, in human adults and published 
since year 2001. Pre-specified inclusion/exclusion criteria will identify study types, 
such as randomized controlled trials (RCTs), observational and retrospective studies 
reporting incidence/prevalence, risk factors and complications of T2DM patients in 
India. Two researchers will independently extract the data and analysis of comparable 
outcomes will be carried out as per appropriate statistics along with critical appraisal 
of the studies. Meta-analysis will be done using RevMan (v5.0) Results: Though 
there have been several studies assessing incidence/prevalence, complications and 
risk factors for T2DM, a systematic review/meta-analysis of the evidence is lacking 
in the Indian scenario. This study aims to provide the much-needed evidence link-
ing incidence/prevalence, complication and risk factors in different groups of T2DM 
patients. This study hopes to demonstrate association of various risk factors with 
disease progression and with complications of T2DM. ConClusions: The prevalence 
of T2DM has been increasing over the years. The data from published studies will 
hopefully answer some of the prevailing variations and trends in prevalence of T2DM 
between different subgroups of T2DM patients and their association with risk factors.
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objeCtives: To review lifestyle and genetic factors during pregnancy and early child-
hood in South Asian population living in Europe that may influence later risks of 
insulin resistance, metabolic syndrome, T2DM and CVD Methods: A systematic 
search, using controlled and free terms (i.e.- metabolic-syndrome, glucose-intol-
erance, diabetes-mellitus, pregnancy, foetal development, life-style, nutrition) was 
conducted in Medline, Centre for Reviews and Dissemination and Cochrane Library 
databases. It was completed by pearling and hand-searching. Two reviewers assessed 
independently the results retrieved in the search, to adopt a decision on inclusion/
exclusion. The quality of included papers was appraised with STROBE checklist for 
than the non-AI population. Since the comparison was unmatched, results should be 
interpreted with caution. Ongoing analysis will include a detailed data assessment, 
with a stronger comparison against matched non-AI populations.
PDB16
Real woRlD inciDence of tyPe 2 DiaBetes (t2D) comPlications leaDing 
to hosPitalization in fRance: the RecoDe stuDy
Bouee S.1, Cochinaire A.1, Godard C.2, Sabater F.J.2, Amelineau E.2, Emery C.3, Cotté F.E.2
1Cemka, Bourg la Reine, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3Cemka Eval, 
Bourg La Reine, France
objeCtives: To estimate the cumulative incidence and cost of cardiovascular (CV) 
complications (stroke, acute coronary syndrome (ACS), acute heart failure (AHF) 
and peripheral vascular disease (PVD)) leading to hospitalization in T2D patients 
with a CV complication history in France. Methods: We conducted an analysis of 
the Program for a Medicalized Information System (PMSI) databases which record 
all hospitalizations occurring in France including rehabilitation care. We identi-
fied all patients with a T2D diagnosis and hospitalized for any reason in 2006-2008 
and selected patients with a documented CV complication history. We analyzed 
those patients as a retrospective cohort followed-up for 3 years from the index 
date (January 1st 2009) and calculated cumulative incidences of new CV complica-
tions. We considered death as a competing event. Mean hospital and rehabilitation 
costs were based on the National Scale of Costs. Results: A total of 1,114,182 T2D 
patients were hospitalized in France in 2006-2008. Among them, 30.5% (n= 339,328) 
had a CV complication history. Mean age was 70.6 (+/-11.1), and 61.9% were males. 
Hypertension, dyslipidemia, renal impairment and obesity were reported in 
80.1%, 45.0%, 33.3% and 29.2% of the patients, respectively. The 3-year cumulative 
incidences for one or more new CV complication were: 3.6% [95%CI:3.5%;3.7%] for 
stroke, 5.6% [95%CI:5.5%;5.7%] for ACS, 6.8% [95%CI:6.7%;6.9%] for AHF and 15.0% 
[95%CI:14.9%;15.1%] for PVD with a mean cost per event of € 5,724, € 5 315, € 4 726, € 4 
766, respectively. 21.8%, 10.5%, 11.4% and 9.5% of patients required rehabilitation 
care for stroke, ACS, AHF and PVD, at an additional mean cost of € 12,000, € 6 233, € 6 
987 and € 9 219 per patient, respectively. ConClusions: CV complications represent 
an important burden for T2D patients and the health system in France. These results 
would be helpful for health technology assessment and for economic evaluation of 
upcoming interventions which reduce CV risk in T2D patients.
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objeCtives: While concerning to diabetic treatment, any suboptimum therapy may 
lead to medication error (ME). Objective of study was to report the causes, severity, 
increase in cost of therapy and outcomes of ME in patients undergone treatment for 
diabetes in medicine ward of a community hospital. Methods: Prospective obser-
vational study (8 months). In-patients with type-II diabetes mellitus were chosen 
randomly and the details were followed till discharge. Results: Incidences of 504 
MEs were observed in 164 out of total patient pool of 230. The notable trends in MEs 
identified were- erroneous prescriptions 101(20.03%), inappropriate dosage-form 
93(18.4%), incorrect-route 63 (12.5%), incident of drug interactions 129 on 55 patients 
(10.09%), failure to monitor lab levels 27(5.30%), failure to adjust doses according to 
lab levels 37(7.14%) and 21(4.16%) cases of incorrect-indications. On severity scale, 
MEs were classified as 143(28.37%) severe, 256(50.79%) moderate and 105(20.8%) mild. 
Predicted error outcome of 164 incidences which were reaches to patient classified 
as- no serious 85(51.8%), moderately serious 61(37.19%), 9(5.3%) life threatening and 
9(5.35%) death (predicted). We observed fair degree of linear correlation between 
increasing age and occurrence of ME 0.99 (rcritical value-0.878). Female sex was found 
to be at higher risk of MEs than male (X2= 6.73, P-value= 0.01). There was a linear 
correlation observed between the polypharmacy and ME 0.95 ( rcriticalvalue-0.44). It 
was observed that, out of total 129 drug interactions identified; only 35(27.13%) were 
moderate, while 72(55.81%) were severe and 22(17.05%) found mild. Significant incre-
ment in the length of stay in hospital and direct drug cost were observed among the 
severe, moderately severe and in mild cases. ConClusions: The observed finding 
of ME defines specific clinical domains and patient subgroups for which aggressive 
efforts needed to reduce MEs. Through information dissemination and education, 
managed health care professionals should play more active role in ME-reduction.
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objeCtives: Type 2 diabetes (T2D) and its consequences are largely studied world-
wide. The number of diabetic patients is increasing and thus, a growing number 
of health care resources are needed to cover the treatment of this population. It is 
also known that in spite of the national treatment guidelines, the recommended 
HbA1c level (< 6.5%/48 mmol/mol) is not always achieved. In order to allocate the 
resources effectively, local information concerning epidemiological and demographic 
differences across different jurisdictions must be available. Methods: A national 
population-based study (Finriski 2007) was used to estimate the prevalence of dia-
betes in different geographical areas. The estimated prevalence rates and number 
of T2D patients were extrapolated to municipal level using demographic data from 
the official statistics. UKPDS risk equation was used to predict the number of cardio-
vascular events with and without proper treatment in each municipality. Local risk 
profile and different HbA1c levels (6.5% (48 mmol/mol) and 8.0% (64 mmol/mol)) were 
used to illustrate the importance of treating patients to target. A map-based applica-
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objeCtives: In Type 1 diabetic (T1D) patients high values of glycated hemoglobin 
(HbA1c) have been shown to be associated with higher risk of complications 
leading to high costs to the National Health Care System (NHS). The aim of this 
analysis is to evaluate the economic impact of poor glycaemic control, and the 
potential savings associated with better glycemic control in the Italian T1D popula-
tion. Methods: A probabilistic model using published risk-curves was developed 
to project incidence and progression of diabetes-related complications associated 
with different HbA1c levels over 1-year and 5-year time-horizon in T1D patients. 
Associated cost of retinopathy, nephropathy, neuropathy, cardiovascular disease, 
diabetic ketoacidosis and severe hypoglycemia in the Italian setting were used to 
estimate the economic impact of complications in each HbA1c interval form the 
NHS perspective. Subsequently the results of the simulation were translated to 
the entire Italian T1D population stratified by HbA1c level accordingly to published 
2012 data. Results: Estimated cost per patients of diabetes-related complica-
tions in the first year of occurrence, stratified by HbA1c intervals, ranged from 
4,463€ for HbA1c ≥ 10% to 2,006€ for HbA1c between 7% and 8%. A 5 year follow 
up analysis was also conducted. A treatment strategy able to reduce HbA1c level 
from ≥ 10% to 9% could lead to potential savings of 1,342€ per patients in the first 
year of treatment. Considering the total T1D Italian population, improving HbA1c 
to < 8% in the first year would results in a potential savings of about 17 million 
euros. ConClusions: The economic impact of diabetes-related complications in 
the Italian setting is significant. Consequently the potential savings for the NHS 
derived from the implementation of strategies aimed at improving HbA1c in T1 
should be considered. Moreover the greater the reduction of Hba1c obtained the 
greater the associated savings.
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objeCtives: Cost comparison between different basal insulin regimens (Glargine 
vs. Detemir vs. NPH-insulin) in diabetic patients in Germany under real-life condi-
tions. Methods: The analysis is based on IMS LRx-database (2011). This repre-
sentative patient tracking tool covers nearly 60 million insurants and includes 
more than 500 million drug prescriptions per year (including consumables) 
Patients with at least two prescriptions of basal insulin (Glargine, Detemir or 
NPH-insulin) in 2011 (January – December) and at least one prescription of any 
type in 2010 and 2012 were considered eligible. Costs included basal and bolus 
insulin, oral antidiabetic drugs, test strips, needles and lancets and were esti-
mated by ex pharmacy prices (Lauer Taxe) minus legally defined rebates according 
to §130 a of social security code (SGB V). Results: A total of 542.438 patients 
were allocated to either Glargine (207.506 patients) or Detemir (90.671 patients) 
or NPH (244.261 patients). The mean annual treatment costs per patient are 1.211 
€ (Glargine), 1.224 € (NPH insulin) and 1.572 € (Detemir). A breakdown at the level 
of different sick funds shows a similar pattern of annual treatment costs per 
patient of the three basal insulin regimens. The acquisition costs of basal insu-
lin is considerably higher for Glargine (380 € ) and Detemir (448 € ) compared to 
NPH-Insulin (253 € ). The cost of bolus insulin is lower in the Glargine group (305 
€ ) compared to NPH-insulin (419 € ) and Detemir (493 € ). Costs of consumables 
(test strips, needles, lancets) are lowest in the in the Glargine group (395 € ) due 
fewer insulin applications compared to Detemir (509 € ) and NPH insulin (461 
€ .) ConClusions: Mean annual treatment costs are lowest with Glargine fol-
lowed by NPH-insulin, whereas Detemir based regimens are 30% more expensive 
under real life conditions. The results are in line with previous cost analyses in 
diabetic patients in Germany [1-3]
PDB26
a comPaRison of the economic BuRDen anD health caRe utilizations 
of veteRan Patients DiagnoseD with DiaBetes in the uniteD states
Xie L.1, Wang L.2, Kariburyo M.F.1, Huang A.2, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
3STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA
objeCtives: To assess the economic burden and health care utilizations of 
diabetes in the U.S. veteran population. Methods: Adult (≥ 18 years of age) 
patients diagnosed with diabetes (International Classification of Disease 9th 
Revision Clinical Modification [ICD-9-CM] code 250.x0 or 250.x2) were identi-
fied from the dataset between October 1, 2009 through September 30, 2011. The 
first diagnosis date was designated as the index date. A comparator group was 
created consisting of patients without diabetes but of the same age, region, 
gender and index year, and matched by baseline Charlson Comorbidity Index. 
The index date for the comparator group was randomly selected to minimize 
selection bias. Continuous medical and pharmacy benefits 1 year pre- and 1 year 
post-index date were required for patients in both groups. One-to-one propensity 
score matching (PSM) was applied to compare health care costs and utiliza-
tions during the follow-up period between the diabetes and comparator groups, 
adjusted for baseline demographic and clinical characteristics. Results: A total 
of 1,427,948 patients were identified for the diabetes and comparator cohorts. 
After applying 1:1 PSM matching, a total of 340,933 patients were matched from 
each group, ensuring well-balanced baseline characteristics. Patients diagnosed 
with diabetes were more likely to report inpatient (8.93% vs. 2.09%, p< 0.01), emer-
gency room (13.66% vs. 5.61%, p< 0.01), outpatient (99.63% vs. 53.78%, p< 0.01), 
and pharmacy visits (87.13% vs. 52.69%, p< 0.01). They also incurred higher 
health care costs, including inpatient ($3,031 vs. $582, p< 0.01), emergency room 
($137 vs. $51, p< 0.01), outpatient ($3,375 vs. $1,272, p< 0.01), pharmacy ($708 vs. 
$293, p< 0.01) and total costs ($7,113 vs. $2,148, p< 0.01) than the comparator 
group. ConClusions: U.S. veteran patients diagnosed with diabetes reported 
a significantly higher economic burden compared to the matched controls over 
a 12-month period.
observational studies and Centre for Evidence Based Medicine checklists for any 
other study design. The present review is part of the GIFTS project funded by Seventh 
Framework Programme of European Commission. Results: A total of 349 papers 
were identified, after title and abstract revision 76 full text were retrieved plus 8 
identified through pearling. To date 67 full texts have been assessed, 49 excluded and 
18 included. 14 (78%) were conducted in the UK. South Asian pregnant women were 
at higher risk of developing GDM (OR ranged 2-5.6) and intrauterine growth retarda-
tion (OR ranged 2-5) than European counterparts. These factors contributed to higher 
rates of stillbirth, perinatal and neonatal mortality and congenital anomalies detected 
in South Asian origin women. As well as higher rates of babies with vitamin D defi-
ciency, hypocalcaemia, hyperinsulinemia, dyslipidaemia, hypoglycaemia and lower 
birthweight. Also higher risk of rapid weight gain between 12 to 24 months and 3 to 
5 years in Asian infants was reported in two different papers. ConClusions: There 
are differences between Asian women living in Europe and European women during 
pregnancy, and their offspring, which as early life factors might explain higher preva-
lence of later metabolic syndrome and type 2 diabetes in Asian migrant population.
PDB22
PReDicting the fRequency of seveRe anD non-seveRe hyPoglycaemia 
in insulin tReateD tyPe-2 DiaBetes suBjects
McEwan P.1, Foos V.2, Grant D.3, Palmer J.L.4, Varol N.5, Curtis B.6, Boye K.S.7
1Swansea University, Cardiff, UK, 2IMS Health, Basel, Switzerland, 3IMS Health, London, UK, 4IMS 
Health, Allschwil, Basel-Landschaft, Switzerland, 5Eli Lilly and Company, Windlesham, Surrey, 
UK, 6Eli Lilly & Co., Indianapolis, IN, USA, 7Eli Lilly and Company, Indianapolis, IN, USA
objeCtives: Recent studies have quantified the resource implications associated 
with severe hypoglycaemia episodes (SHE) and non-severe hypoglycaemia episodes 
(NSHE). The objective of this study was to characterize the relationship between the 
frequency of SHE/NSHE and patient/therapy characteristics in insulin treated type-2 
diabetes mellitus (T2DM) patients. Methods: We conducted a literature review of 
the MEDLINE database for insulin-based T2DM clinical trials where sulfonylurea usage 
was also reported between June 1, 2007 and June 1, 2012. Patient demographics, treat-
ments effects and treatment type were extracted and the SHE/NSHE rate per 100 
patient years (PY) was modeled via a log-linear regression model using R. Results: 
Data were extracted from 82 studies for a total of 155 trial arms meeting the search 
criteria; treatment regimes were categorized into basal analog (30%); bolus analog 
(4%); basal bolus (24%); biphasic analog (25%); biphasic human (8%) and NPH (10%). 
Mean (standard deviation) age was 57.9 (3.8) years; 10.2 (2.4) years duration of diabe-
tes; 8.8% (0.7)baseline and 7.5% (0.5) end-of-study HbA1c respectively. Mean reported 
NSHE/100 PYs was 929.8. The final regression model was NSHE/100PY= exp(14.771 
- 0.088 × age - 0.667 × baseline HbA1c + 0.427 × HbA1c reduction + 0.189 × duration 
diabetes + 0.007 × % study allowed sulphonylurea – 0.545 × basal analog insulin) with 
an R2 goodness of fit of 0.226. Mean reported SHE/100 PYs was 5.9. The final regression 
model was SHE/100PY= exp(10.794 - 0.101 × age - 0.723 × baseline HbA1c + 0.638 × 
HbA1c reduction + 0.163 × duration diabetes + 0.768 × biphasic insulin )-1 with an 
R2of 0.219. ConClusions: This study provides a basis for predicting the number of 
SHE and NSHE in insulin treated T2DM subjects. When linked to resource and quality 
life, these equations may facilitate the improved estimation of the health economic 
burden associated with SHEs and NSHEs.
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objeCtives: Severe (requiring assistance from another individual) hypoglycaemic 
events (SHEs) are important from both clinical and economic perspectives. The aim 
was to assess treatment-related SHEs risk in different treatment regimens in type 1 
and 2 diabetes. Methods: Anti-diabetic treatments were stratified into six groups: 
basal-bolus (BB); basal in combination with oral therapy (BOT); insulin pumps; bipha-
sic insulin; sulfonylureas; other than SU oral antidiabetic drugs (OADs). Insulin treat-
ments were further split into analogues (IA) and human insulins (HI). The systematic 
review of Medline, EMBASE and Cochrane databases was conducted for recent (≤ 10 
years), large (n ≥ 100), observational studies. Data on time horizon, participants num-
ber and SHEs occurrence were extracted. Using a random effects Poisson model within 
MCMC framework we estimated the SHEs rates. Results: In the systematic review 
5220 publications were found, 525 full texts evaluated and 101 articles included (55 
trials). The following average SHE/year (No of studies; 95%CI) were estimated: Type 1: 
BB with IA as the basal component: 0.53 (7; 0.29–1.18); BB with HI: 1.10 (6; 0.58–2.71); 
pump treatment: 0.18 (14; 0.13–0.25); biphasic insulin: 1.10 (0.58–2.71). Type 2: BOT 
with IA as the basal component: 0.13 (11; 0.04–1.17); BOT with HI: 0.21 (7; 0.08–0.88); 
BB with IA: 0.01 (6; 0.003–0.25); BB with HI: 0.56 (3; 0.16–9.65); biphasic IA: 0.10 (12; 
0.05–0.26); biphasic HI: 0.20 (6; 0.07–0.93); sulfonylureas: 0.05 (6; 0.02–0.14); OADs: 0.01 
(0.001–0.008). The differences in the SHEs risk among regimens were significant at a 
95% level. ConClusions: The SHEs risk differs in both type 1 and 2 diabetes across 
various treatment regimens. HI was found to increase the SHEs risk compared to IA. 
Limited availability of studies and heterogeneous data make it difficult to come up 
with precise rate estimation for typical anti-diabetic treatment regimens.
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PDB24
estimation of the cost of comPlications RelateD to glycateD 
hemogloBin in the italian DiaBetes tyPe 1 PoPulation
Nicolucci A.1, de Portu S.2, Orsini Federici M.3, D’Ostilio D.3
1Mario Negri Sud, Santa Maria Imbaro, Italy, 2Medtronic International Sàrl, Tolochenaz, 
Switzerland, 3Medtronic Italia SpA, Sesto San Giovanni, Italy
